You are viewing an incomplete version of our website. Please click to reload the website as full version.

Betacellulin antibody (BTC) (AA 17-45)

Details for Product anti-BTC Antibody No. ABIN655615, Supplier: Log in to see
Antigen
  • Bcn
  • BTC
  • LOC100228121
  • probetacellulin
Alternatives
anti-Human Betacellulin antibody for ELISA
Epitope
AA 17-45, N-Term
9
7
7
6
5
5
3
1
1
Reactivity
Human
83
13
3
2
2
Host
Rabbit
77
11
2
1
1
Clonality (Clone)
Polyclonal ()
Conjugate
This Betacellulin antibody is un-conjugated
12
4
2
2
1
1
1
1
1
1
1
1
1
1
1
Application
Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
58
37
17
11
9
6
6
5
3
3
3
2
2
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen This BTC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 17-45 AA from the N-terminal region of human BTC.
Clone RB14431
Isotype Ig
Specificity This BTC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 24-54 amino acids from the N-terminal region of human BTC.
Purification This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Alternative Name BTC (BTC Antibody Abstract)
Background The protein encoded by this gene is a member of the EGF family of growth factors. It is synthesized primarily as a transmembrane precursor, which is then processed to mature molecule by proteolytic events. This protein is a ligand for the EGF receptor.
Synonyms: RB14431
Pathways: ErbB signaling pathway
Molecular Weight 19746 Da
Gene ID 685
UniProt P35070
Research Area Cell Signaling, Protein Modifications, Cell Structure, Cell Cycle
Pathways RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
Application Notes WB = 1:1000, IHC (p) = 1:10-50, IF = 1:10-50, FACS = 1:10-50
Restrictions For Research Use only
Format Liquid
Concentration 2 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date 6 months
Supplier Images
Immunofluorescence (IF) image for anti-Betacellulin antibody (BTC) (AA 17-45) (ABIN655615) Confocal immunofluorescent analysis of BTC Antibody (N-term)(ABIN655615) with MDA-MB2...
Background publications Stoeck, Shang, Dempsey: "Sequential and gamma-secretase-dependent processing of the betacellulin precursor generates a palmitoylated intracellular-domain fragment that inhibits cell growth." in: Journal of cell science, Vol. 123, Issue Pt 13, pp. 2319-31, 2010

Genetos, Rao, Vidal: "Betacellulin inhibits osteogenic differentiation and stimulates proliferation through HIF-1alpha." in: Cell and tissue research, Vol. 340, Issue 1, pp. 81-9, 2010

Nagaoka, Fukuda, Hashizume, Nishiyama, Tada, Yamada, Salomon, Yamada, Kojima, Seno: "A betacellulin mutant promotes differentiation of pancreatic acinar AR42J cells into insulin-producing cells with low affinity of binding to ErbB1." in: Journal of molecular biology, Vol. 380, Issue 1, pp. 83-94, 2008

Moss, Bomar, Liu, Sage, Dempsey, Lenhart, Gillispie, Stoeck, Wildeboer, Bartsch, Palmisano, Zhou: "The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events." in: The Journal of biological chemistry, Vol. 282, Issue 49, pp. 35712-21, 2007

Révillion, Lhotellier, Hornez, Bonneterre, Peyrat: "ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis." in: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Vol. 19, Issue 1, pp. 73-80, 2007